Kisspeptin-10
Also known as: KP-10, Human metastin 45-54
At a glance
PeptiGuide dataset · reviewed Aug 2026
What it is
KISS1-derived peptide signal studied for reproductive hormone regulation.
Status
Clinical Trials
Typical dose
100–200mcg
Researched for
Fertility, testosterone, reproductive hormone optimization
Trial progress
- PrePreclinical
- IPhase I
- IIPhase II
- IIIPhase III
- IVPhase IV
- FDAFDA approved
Phase I - Emerging human evidence with important limitations
Use the tools
Stay current
Get updates on Kisspeptin-10
New studies, regulatory decisions and data corrections - delivered when they land.
In plain language
- KISS1-derived family that includes kisspeptin-54 and shorter active fragments KP-14, KP-13, and KP-10.
- Source status: investigational, not FDA approved, with human-trial evidence reported.
- Extracted typical dose: 100-200 mcg subcutaneously once daily; source also lists IV research use and investigational use.
- Researched for fertility, testosterone, and reproductive hormone optimization.
How it's thought to work
Kisspeptin is described as acting through KISS1R/GPR54 receptors on GnRH neurons in the hypothalamus. The reported intracellular pathway includes phospholipase C activation with IP3 and DAG second messengers, followed by increased GnRH release. GnRH then drives pituitary gonadotropin output, including LH and FSH, linking kisspeptin signaling to ovarian and testicular hormone regulation. The source also notes genetic evidence: inactivating KISS1 or KISS1R mutations are associated with pubertal failure and infertility, while activating mutations are associated with precocious puberty.
What the research shows
Where the research stands
The supplied evidence reports several human research contexts. In women with hypothalamic amenorrhea, kisspeptin-54 was reported to raise LH about 10-fold and FSH about 2.5-fold into the normal range, and infusion protocols were reported to restore LH pulse frequency. In an IVF setting, kisspeptin-54 was used to trigger oocyte maturation, with a live term birth reported, and the source says it has been explored as a potentially gentler trigger with possible ovarian hyperstimulation risk reduction. In hypogonadal men, kisspeptin-10 infusion reportedly increased LH roughly 5-fold and moved testosterone into the normal range. The same source cautions that these data mainly come from small academic studies and specialist infusion protocols, not large multi-center phase 3 trials, and that short-term hormone changes do not establish long-term safety.
What it shows
✓ Human studies
Emerging human evidence with important limitations
△ Limitations
Study protocols describe research and are not dosing recommendations.
Bottom line: Investigational - Clinical trials ongoing Not FDA Approved
Typical dosing
CommunityCommunity dataset100–200 mcg
subcutaneously once daily
Community-reported entry describes subcutaneous injection to the abdomen or thigh, morning use for hormone-rhythm alignment, 4-6 week cycles, and starting at 50-100 mcg with adjustment based on response. It also reports use alongside TRT to support fertility through hypothalamic GnRH signaling.
Research dosing
Study-specific protocolsHuman trials under way - protocols are study-specific
Timing & administration
Best time to take
Morning or as directed
As clinically directed
Food recommendation
With or without food
Why this timing?
Because kisspeptin is reported to influence reproductive hormone signaling, the source notes that timing may depend on the specific research or clinical goal.
Possible side effects
Not everyone experiences these. Individual responses vary with dose, duration, and personal factors.
- Generally very well-tolerated
- No serious adverse events in trials
- Temporary flushing
- Mild headache
- Nausea
- Long-term hormonal effects unknown
Not everyone experiences side effects, and severity can vary by context, purity, route, and individual health factors.
Sources
Frequently asked questions
Sequence
H-Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-Arg-Phe-NH2 (YNWNSFGLRF)
One open dataset
Every fact on this page - doses, side effects, references - comes from the same PeptiGuide dataset that powers the Tracker, Compare, and the Lab.
Browse the datasetEducational resource, not medical advice. Talk to your clinician before acting on anything here.
Community discussion
Comments are moderated before they appear. Keep it evidence-focused.